MOSCOW, Oct 16 (PRIME) -- The Federal Antimonopoly Service has approved the sales price limit on Favipiravir at 100 rubles per pill, or 5,500 rubles value-added tax (VAT) inclusive per a 50 pill pack, the authority said in a statement on Friday.
"The Federal Antimonopoly Service has set the sales price limit for the first two producers of a pharmaceutical for COVID-19 with an international non-patented name Favipiravir,” the authority said.
“The decision to set the price at 100 rubles per pill was agreed by all members of the Committee of the Healthcare Ministry of Russia for the lists of drugs in the presence of representatives of the producers."
The price of Favipiravir in the pharmacies is expected to fall to 6,875 rubles with markups from 16,306 rubles, the highest price registered as of Friday.
(77.9461 rubles – U.S. $1)
End %%mk/jst%%
|
|
